SecBot SecBot
Institutional Cluster

ABUS

Arbutus Biopharma Corp
MIXED
Impact 4/10
Horizonweeks Processed3mo ago
Institutional cluster: 3 buyers, 2 sellers (mixed)
Actionable Insight ◆ Mixed

Monitor for further 13F filings from other large holders (BlackRock, State Street) to see if Morgan Stanley's trim is an isolated rebalance or the start of broader institutional distribution. The LNP patent litigation catalyst against Pfizer/BioNTech (announced in the Aug 12 8-K) could attract new activist or event-driven buyers, but the lack of insider buying and poor historical performance of bullish calls on ABUS suggest waiting for confirmation before initiating a position.

DirectionMixed
Confidencemedium
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$4.71
T+0 close · Aug 15, 2026 · via day close
Latest settled
−18.90%
T+60 · $3.82
Vs SPY
−15.95%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 17 $4.71entry
  2. T+1 · 3mo ago +2.76%α +3.44% · $4.84
  3. T+5 · 3mo ago +10.40%α +11.59% · $5.20
  4. T+20 · 2mo ago +7.43%α +9.41% · $5.06
  5. T+60 · 7d ago −18.90%α −15.95% · $3.82

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Three asset managers (Fidelity, Russell, Nuveen) added small positions in ABUS during Q2 2026, totaling $2.0M in net buying, while two sellers (Morgan Stanley and Zurcher Kantonalbank) trimmed $31.9M, creating a net outflow of ~$29.9M. The buying cluster is dwarfed by Morgan Stanley's 31.6% reduction of its $116.5M stake, suggesting institutional conviction is mixed despite the Q2 earnings beat and Moderna settlement catalyst. The net institutional flow is bearish in magnitude, but the small buyer cluster may reflect selective interest in the LNP patent litigation catalyst against Pfizer/BioNTech announced in the August 8-K.

Key Financial Metrics

Direction
distributing
Buy Value
$2.0M
Sell Value
$31.9M
Net Flow
-$29.9M

Institutional Positions

Net institutional flow: -$29.9M

▲ Buyers (3)

InstitutionActionChangePosition ValueValue Δ
FidelityADD+84.1%$1.3M$629.0K
Russell Investments GroupDOUBLED+160.9%$284.0K$182.0K
NuveenADD+91.7%$2.4M$1.2M

▼ Sellers (2)

InstitutionActionChangePrev ValueValue Δ
Morgan StanleyTRIM-31.6%$116.5M-$31.6M
Zurcher Kantonalbank (Zurich Cantonalbank)TRIM-55.9%$564.0K-$298.4K

Key Facts

  • 3 institutions added $2.0M in ABUS positions during Q2 2026 (Fidelity +$629K, Nuveen +$1.2M, Russell +$182K)
  • Morgan Stanley trimmed 31.6% of its stake, selling $31.6M worth, reducing its position from $116.5M to $85.0M
  • Zurcher Kantonalbank trimmed 55.9% of its position, selling $298K
  • Net institutional outflow of ~$29.9M (buyers $2.0M vs sellers $31.9M)
  • No open-market insider buying in the window (confluence score 19/100, institutions only)

Financial Impact

Net institutional outflow of ~$29.9M: 3 buyers added $2.0M while 2 sellers trimmed $31.9M

institutional ownershipfloat

Risk Factors

  • Morgan Stanley's large trim may signal fundamental concerns not captured in the Q2 earnings beat
  • No insider buying to corroborate the institutional buying thesis
  • The Moderna settlement cash ($178.4M) is a one-time event and does not change the operational trajectory

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 institutional 13F filing from SEC EDGAR.

DocumentAccession Number
INST-CLUSTER Data (Synthetic)inst-cluster-ABUS-2026-Q2

Track record

25 reports on ABUS

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +11.55% at T+20 after the Aug 12, 2026 report. 6 of 12 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $4.04 settles Feb 16
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $4.04 settles Feb 16
  3. Nov 16, 2026today SC 13G Neutral 3/10 Entry $4.07 settles Feb 12
  4. Nov 12, 20264d ago 8-K Neutral 2/10 Entry $4.03 settles Feb 10
  5. Nov 10, 20266d ago 8-K Neutral 5/10 Entry $3.82 settles Feb 8
  6. Nov 10, 20266d ago Press Release Neutral 4/10 No price data
  7. Nov 6, 202610d ago Institutional Cluster Bearish 4/10 Entry $3.66 settles Feb 4
  8. Oct 22, 202625d ago 8-K Bullish 6/10 Entry $4.21 settles Jan 20
  9. Oct 22, 202625d ago Press Release Bullish 7/10 Entry $4.21 settles Jan 20
  10. Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $4.18 settles Jan 5
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 12m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 15, 2026